by JG Staal
•Development of Algorithms & Classification system for Diabetes, Cardiovascular, Oncology, COPD, Osteoporosis and Chronic Pain.
•Prototype in app stores with positive feedback on concept as well as willingness to pay.
•Started development of MVP.
Co-Founder & CEO, MD
Biography: Over 25 years of experience in: - Practicing medicine (Primary Care practice). - Peer-reviewing Medical Research. - Participating as TedMed Research Scholar. - Starting and scaling successful companies (DoloTest).
Title: Co-Founder & CEO
Advanced Degree(s): MD
For caregivers and patients it is typically impossible and in addition very frustrating to identify clinically meaningful clinical trials. Zignifica helps patients and caregivers to find relevant clinical research and provides a classification system (from A through F) to easily understand the clinical significance of that research.
Zignifica helps providers find relevant clinical research (leveraging AI and Machine Learning) and easily understand the clinical significance through a proprietary and industry-first classification system, so they can spend less time on doing research and more time seeing patients while delivering better care at the same time.
We want to partner with Health systems in the USA and in Europe to trial our MVP in a primary care setting. Initially this will be through physicians logging into the solution, but can be followed by API based solution that will integrate with EMR to identify relevant and trustworthy clinical research for patient/treatment.
January 2016: Idea initiation and start of building algorithms for determining clinical significance
June 2016: Validated & Confirmed concepts during Evidence Based Medicine conference in Oxford, UK
December 2016: Finalized algorithms for Chronic Pain, Diabetics and Cardiology
December 2016: Filed provisional patent
January 2017: Founded Zignifica
February 2017: Finalized algorithms for Oncology
March 2017: Prototype in the App Store and in Google Play
April 2017: Winner hackathon at IBM Watson/Galvanize Cognitive Builder Faire
August 2017: Awarded by StartUp Health to join their group of moonshot companies.
Unlike other clinical research tools, Zignifica allows, as an Industry-first, the ability for the physician to identify trustworthiness of research as well as the relevance of research to a specific patient/treatment.
It will take significant time for others to:
We have self funded the company thus far.
Zignifica is part of StartUp Health’s Global Army of Health Transformers.
Zignifica is part of the IBM Global Enterpreneur Program.
Total addressable market is $1.1 billion based on markets in USA, Canada, Europe and Australia.
Projected 3 Year Growth
We sell our solution to physicians in Canada, USA, Europe and Australia. Our initial focus will be on primary care.
Our recurring revenue comes from a monthly subscription fee per physician.
Unlike other clinical research tools, Zignifica allows, as an Industry-first, the ability for the physician to identify trustworthiness of research and relevance of research to a specific patient/treatment. We focus on clinical significance, rather than statistical significance.
We have received initial positive feedback on our prototype (available in AppStore and Google Play) on both the concept as well as the willingness to pay.
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.
No updates found .